HRP20130892T1 - Farmaceutske formulacije i njihove upotrebe u lijeäśenju ženske seksualne disfunkcije - Google Patents
Farmaceutske formulacije i njihove upotrebe u lijeäśenju ženske seksualne disfunkcije Download PDFInfo
- Publication number
- HRP20130892T1 HRP20130892T1 HRP20130892TT HRP20130892T HRP20130892T1 HR P20130892 T1 HRP20130892 T1 HR P20130892T1 HR P20130892T T HRP20130892T T HR P20130892TT HR P20130892 T HRP20130892 T HR P20130892T HR P20130892 T1 HRP20130892 T1 HR P20130892T1
- Authority
- HR
- Croatia
- Prior art keywords
- testosterone
- combination
- dihydrotestosterone
- use according
- pde5
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 9
- 206010057671 Female sexual dysfunction Diseases 0.000 title claims 3
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 40
- 229960003604 testosterone Drugs 0.000 claims 20
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims 13
- 229960003473 androstanolone Drugs 0.000 claims 13
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 10
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 10
- 229940079593 drug Drugs 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims 8
- 230000001568 sexual effect Effects 0.000 claims 6
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 229960003310 sildenafil Drugs 0.000 claims 4
- 229960000835 tadalafil Drugs 0.000 claims 4
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims 4
- 229960002381 vardenafil Drugs 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 3
- 230000001800 adrenalinergic effect Effects 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 229960003638 dopamine Drugs 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 claims 1
- 102100030758 Sex hormone-binding globulin Human genes 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Primary Health Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Business, Economics & Management (AREA)
- Tourism & Hospitality (AREA)
- Medicinal Preparation (AREA)
- Child & Adolescent Psychology (AREA)
- Economics (AREA)
- Human Resources & Organizations (AREA)
- Marketing (AREA)
- Strategic Management (AREA)
- Physics & Mathematics (AREA)
- General Business, Economics & Management (AREA)
Claims (22)
1. Kombinacija od PDE5-inhibitora i testosterona ili dihidrotestosterona, naznačena time, da se upotrebljava kao lijek za liječenje ženske seksualne disfunkcije, pri čemu se testosteron primjenjuje 3,5 do 5,5 sati prije seksualne aktivnosti ili se dihidrotestosteron primjenjuje 3 do 5 sati prije seksualne aktivnosti, dok se PDE5-inhibitor primjenjuje 1 do 2 sata prije seksualne aktivnosti, tako da se učinci tih spojeva barem djelomično preklapaju.
2. Kombinacija za uporabu prema zahtjevu 1, naznačena time, da se testosteron ili dihidrotestosteron formuliraju za dobivanje vršne vrijednosti slobodnog testosterona ili dihidrotestosterona u cirkulaciji krvi od najmanje 0,010 nmol/l kod pacijenta koji pati od seksualne disfunkcije.
3. Kombinacija za uporabu prema bilo kojem zahtjevu od 1 do 2, naznačena time, da se testosteron ili dihidrotestosteron dobavljaju u obliku podjezične recepture.
4. Kombinacija za uporabu prema zahtjevu 3, naznačena time, da spomenuta podjezična receptura sadrži ciklodekstrin, primjerice hidroksipropil-betaciklodekstrin.
5. Kombinacija za uporabu prema bilo kojem zahtjevu od 1 do 2, naznačena time, da je testosteron ili dihidrotestosteron pripremljen za oslobađanje uglavnom cjelokupnog testosterona ili dihidrotestosterona unutar vremenskog perioda od 60 sekundi nakon primjene.
6. Kombinacija za uporabu prema bilo kojem zahtjevu od 1, 2 ili 5, naznačena time, da spomenuti lijek obuhvaća jedan sastav koji sadrži testosteron i jedan sastav koji sadrži PDE5-inhibitor.
7. Kombinacija za uporabu prema bilo kojem zahtjevu od 1, 2 ili 5, naznačena time, da spomenuti lijek obuhvaća jednu kapsulu ili recepturu s različitim svojstvima otpuštanja za dva sastava.
8. Kombinacija za uporabu prema bilo kojem zahtjevu od 1, 2 ili 5 do 7, naznačena time, da spomenuti lijek obuhvaća najmanje 0,3 mg testosterona i najviše 2,5 mg testosterona.
9. Kombinacija za uporabu prema bilo kojem zahtjevu od 1, 2 ili 5 do 8, naznačena time, da spomenuti lijek obuhvaća najmanje 5 mg vardenafila i najviše 20 mg vardenafila.
10. Kombinacija za uporabu prema bilo kojem zahtjevu od 1, 2 ili 5 do 8, naznačena time, da spomenuti lijek obuhvaća najmanje 25 mg sildenafila i najviše 100 mg sildenafila.
11. Kombinacija za uporabu prema bilo kojem zahtjevu od 1, 2 ili 5 do 8, naznačena time, da spomenuti lijek obuhvaća najmanje 5 mg tadalafila i najviše 20 mg tadalafila.
12. Kombinacija za uporabu prema bilo kojem zahtjevu od 1, 2 ili 5 do 11, naznačena time, da spomenuti lijek nadalje obuhvaća spoj koji se nadmeće s testosteronom ili dihidrotestosteronom u vezivanju za SHBG.
13. Kombinacija za uporabu prema bilo kojem zahtjevu od 1, 2 ili 5 do 12, naznačena time, da nadalje obuhvaća agonist dopaminskog prolaza.
14. Kombinacija za uporabu prema bilo kojem zahtjevu od 1, 2 ili 5 do 13, naznačena time, da nadalje obuhvaća inhibiciju adrenergijskog tonusa u centralnom nervnom sustavu.
15. Garnitura od dijelova za uporabu u liječenju ženske seksualne disfunkcije, naznačena time, da se putem nje primjenjuje testosteron 3,5 do 5,5 sati prije seksualne aktivnosti ili se dihidrotestosteron primjenjuje 3 do 5 sati prije seksualne aktivnosti, a PDE5-inhibitor se primjenjuje 1 do 2 sata prije seksualne aktivnosti, tako da se učinci spojeva barem djelomično preklapaju, pri čemu ta garnitura od dijelova sadrži najmanje jedan farmaceutski sastav koji obuhvaća testosteron ili dihidrotestosteron i najmanje jedan farmaceutski sastav koji obuhvaća PDE5-inhibitor, gdje je spomenuti sastav koji obuhvaća testosteron ili dihidrotestosteron, pripravljen za oslobađanje cjelokupnog testosterona uglavnom odmah na ciljanom mjestu.
16. Garnitura od dijelova prema zahtjevu 15, naznačena time, da farmaceutski sastav koji obuhvaća testosteron, sadrži najmanje 0,3 mg testosterona i najviše 2,5 mg testosterona.
17. Garnitura od dijelova prema zahtjevu 15 ili 16, naznačena time, da farmaceutski sastav koji obuhvaća PDE5-inhibitor, sadrži najmanje 5 mg vardenafila i najviše 20 mg vardenafila.
18. Garnitura od dijelova prema zahtjevu 15 ili 16, naznačena time, da farmaceutski sastav koji obuhvaća PDE5-inhibitor, sadrži najmanje 25 mg sildenafila i najviše 100 mg sildenafila.
19. Garnitura od dijelova prema zahtjevu 15 ili 16, naznačena time, da farmaceutski sastav koji obuhvaća PDE5-inhibitor, sadrži najmanje 5 mg tadalafila i najviše 20 mg tadalafila.
20. Garnitura od dijelova prema bio kojem zahtjevu od 15 do 19, naznačena time, da ona nadalje obuhvaća agonist dopaminskog prolaza.
21. Garnitura od dijelova prema bio kojem zahtjevu od 15 do 19, naznačena time, da nadalje obuhvaća inhibiciju adrenergijskog tonusa u centralnom nervnom sustavu.
22. Farmaceutski sastav za uporabu u prema bilo kojem zahtjevu od 1 do 14, naznačen time, da spomenuti farmaceutski sastav obuhvaća PDE5-inhibitor i testosteron ili dihidrotestosteron zapakirane u jednoj kapsuli ili recepturi s različitim svojstvima oslobađanja za dva spoja, tako da se učinci od PDE5-inhibitora i testosterona ili dihidrotestosterona podudaraju.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04076402 | 2004-05-11 | ||
| EP04078033 | 2004-11-04 | ||
| EP04078381 | 2004-12-13 | ||
| EP04078380 | 2004-12-13 | ||
| EP04078455 | 2004-12-21 | ||
| PCT/NL2005/000355 WO2005107810A2 (en) | 2004-05-11 | 2005-05-11 | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130892T1 true HRP20130892T1 (hr) | 2013-11-08 |
Family
ID=35094148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130892TT HRP20130892T1 (hr) | 2004-05-11 | 2013-09-20 | Farmaceutske formulacije i njihove upotrebe u lijeäśenju ženske seksualne disfunkcije |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US8227453B2 (hr) |
| EP (1) | EP1750766B1 (hr) |
| JP (3) | JP2007537247A (hr) |
| KR (1) | KR101292492B1 (hr) |
| CN (2) | CN101027061B (hr) |
| AU (1) | AU2005239962B2 (hr) |
| BR (1) | BRPI0511079A (hr) |
| CA (1) | CA2566699C (hr) |
| CY (1) | CY1114448T1 (hr) |
| DK (1) | DK1750766T3 (hr) |
| ES (1) | ES2429444T3 (hr) |
| HK (1) | HK1108128A1 (hr) |
| HR (1) | HRP20130892T1 (hr) |
| MX (2) | MX347237B (hr) |
| NZ (1) | NZ551356A (hr) |
| PL (1) | PL1750766T3 (hr) |
| PT (1) | PT1750766E (hr) |
| RS (1) | RS52945B (hr) |
| RU (2) | RU2436579C2 (hr) |
| SI (1) | SI1750766T1 (hr) |
| WO (1) | WO2005107810A2 (hr) |
| ZA (1) | ZA200609974B (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0511079A (pt) | 2004-05-11 | 2007-12-26 | Emotional Brain Bv | usos de uma combinação de um inibidor de pde5 e testosterona ou de um seu análogo, e de testosterona ou de um seu análogo, formulação farmacêutica, e, kit de partes |
| EP1790343A1 (en) * | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
| WO2012107090A1 (en) * | 2011-02-10 | 2012-08-16 | Synthon Bv | Granulated composition comprising tadalafil and a disintegrant |
| RU2013141446A (ru) * | 2011-02-10 | 2015-03-20 | Синтон Бв | Фармацевтическая композиция, содержащая тадалафил и циклодекстрин |
| WO2012107092A1 (en) * | 2011-02-10 | 2012-08-16 | Synthon Bv | Pharmaceutical composition comprising tadalafil and a cyclodextrin |
| EA034288B1 (ru) | 2011-05-13 | 2020-01-24 | Эб Ип Хибритабс Б.В. | Система доставки лекарственного средства |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| EP3936133A1 (en) | 2011-11-23 | 2022-01-12 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| WO2013122470A1 (en) * | 2012-02-17 | 2013-08-22 | Emotional Brain B.V. | Methods of differentiating hypoactive sexual desire disorder and/or female sexual arousal disorder |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| KR101484481B1 (ko) * | 2014-08-07 | 2015-01-20 | 주식회사 다림바이오텍 | Pde-5 저해제를 포함하는 설하분무제의 제조방법 및 이에 의하여 제조된 설하분무용 조성물 |
| EP3248592A1 (en) * | 2016-05-25 | 2017-11-29 | EB IP Hybritabs B.V. | Process for the preparation of drug delivery systems having a testosterone compound present in an outer layer or part, as well as such drug delivery systems |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3976776A (en) | 1972-12-06 | 1976-08-24 | Mead Johnson & Company | Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones |
| US4521421A (en) | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
| ZA848005B (en) | 1983-10-17 | 1985-05-29 | Duphar Int Res | Blood-pressure lowering piperazine derivatives |
| US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4640921A (en) | 1986-02-04 | 1987-02-03 | Bristol-Myers | Treatment of sexual dysfunction with buspirone |
| US5015646A (en) | 1987-08-28 | 1991-05-14 | Bristol-Myers Squibb Co. | Pharmaceutically useful polymorphic modification of buspirone |
| US4877774A (en) * | 1987-09-09 | 1989-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Administration of steroid hormones |
| CA1335106C (en) | 1989-02-27 | 1995-04-04 | John Mehnert Schaus | Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes |
| US5447912A (en) | 1989-09-18 | 1995-09-05 | Senetek, Plc | Erection-inducing methods and compositions |
| US5250534A (en) * | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| US5431922A (en) | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
| GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| US5565466A (en) * | 1993-08-13 | 1996-10-15 | Zonagen, Inc. | Methods for modulating the human sexual response |
| RU2152787C2 (ru) | 1994-06-02 | 2000-07-20 | Дан Рига | Лекарство против стресса, против снижения уровня активности и против старения и способ его получения |
| CA2191837C (en) | 1994-06-02 | 2002-10-15 | Dan Riga | Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof |
| BR9607365A (pt) | 1995-03-14 | 1997-12-30 | Vivus Inc | Processo e kit para prevenir disfunção de ereção |
| US5731339A (en) * | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
| AU5671496A (en) | 1995-05-15 | 1996-11-29 | Beth Israel Hospital | Use of dihydrotestosterone compounds for treating male sexual dysfunction |
| GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| US6251436B1 (en) | 1995-09-29 | 2001-06-26 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
| US6242198B1 (en) | 1996-07-25 | 2001-06-05 | Cambridge Neuroscience, Inc. | Methods of treatment of eye trauma and disorders |
| AU756136B2 (en) * | 1997-06-23 | 2003-01-02 | Queen's University At Kingston | Microdose therapy |
| AU740758B2 (en) | 1997-10-28 | 2001-11-15 | Vivus, Inc. | Treatment of female sexual dysfunction |
| US5877216A (en) * | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
| US20040014761A1 (en) * | 1997-10-28 | 2004-01-22 | Place Virgil A. | Treatment of female sexual dysfunction with phosphodiesterase inhibitors |
| US20020013304A1 (en) | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
| US6246436B1 (en) | 1997-11-03 | 2001-06-12 | Agilent Technologies, Inc | Adjustable gain active pixel sensor |
| TW542719B (en) * | 1998-02-23 | 2003-07-21 | Pfizer Res & Dev | Method of treating impotence due to spinal cord injury |
| US6403605B1 (en) | 1998-05-29 | 2002-06-11 | Queen's University At Kingston | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
| UA67802C2 (uk) * | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
| US6087362A (en) * | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
| US7045513B1 (en) * | 1999-03-18 | 2006-05-16 | Genelabs Technologies, Inc. | DHEA composition and method |
| WO2000066114A1 (en) | 1999-04-30 | 2000-11-09 | Lilly Icos Llc | Treatment of female arousal disorder |
| US7258850B2 (en) * | 1999-05-04 | 2007-08-21 | Aradigm Corporation | Methods and compositions for treating erectile dysfunction |
| US6632419B2 (en) * | 1999-05-04 | 2003-10-14 | Aradigm Corporation | Increasing libido in humans via acute testosterone administration |
| US6428769B1 (en) * | 1999-05-04 | 2002-08-06 | Aradigm Corporation | Acute testosterone administration |
| CA2377339A1 (en) * | 1999-06-17 | 2000-12-28 | Armin Johannes Becker | Administration of growth hormone (hgh) for the therapy of sexual functional disorders |
| RU2180591C2 (ru) | 1999-12-24 | 2002-03-20 | Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ | Средство для лечения сексуальных дисфункций у мужчин |
| DE10016548A1 (de) | 2000-04-03 | 2001-10-11 | Bayer Ag | Polyurethan-Dispersionen |
| US6313172B1 (en) | 2000-04-13 | 2001-11-06 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
| US6242436B1 (en) | 2000-06-15 | 2001-06-05 | William Charles Llewellyn | Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans |
| US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| DK1315502T3 (da) | 2000-08-30 | 2010-07-19 | Unimed Pharmaceuticals Llc | Fremgangsmåde til behandling af erektil dysfunktion og til forøgelse af mænds libido |
| US20040092494A9 (en) | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| US20030139384A1 (en) * | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
| CZ299411B6 (cs) | 2000-09-29 | 2008-07-16 | Solvay Pharmaceuticals B. V. | Farmaceutický matricový prípravek vytvárející hydrofilní gel a zpusob výroby tohoto prípravku |
| US20060287335A1 (en) | 2000-11-28 | 2006-12-21 | Wyeth | Serotonergic agents for treating sexual dysfunction |
| US20020107230A1 (en) | 2000-12-22 | 2002-08-08 | Waldon R. Forrest | Methods and formulations for the treatment of female sexual dysfunction |
| US6987129B2 (en) | 2001-03-06 | 2006-01-17 | Cellegy Pharmaceuticals, Inc. | Compounds and methods for the treatment of urogenital disorders |
| IL157009A0 (en) | 2001-03-28 | 2004-02-08 | Pfizer | N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad |
| EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
| US20030027804A1 (en) * | 2001-06-27 | 2003-02-06 | Van Der Hoop Roland Gerritsen | Therapeutic combinations for the treatment of hormone deficiencies |
| US20030022875A1 (en) | 2001-07-27 | 2003-01-30 | Wilson Leland F. | As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US20040259852A1 (en) | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
| JP2007516949A (ja) | 2003-07-16 | 2007-06-28 | ファイザー・インク | 性機能不全の治療 |
| DE60303854T2 (de) | 2003-11-11 | 2006-08-10 | Mattern, Udo | Nasenformulierung mit kontrollierter Freisetzung von Sexualhormonen |
| WO2005094827A1 (en) | 2004-03-30 | 2005-10-13 | Kestrel Pharmaceuticals Inc. | Methods for treating sexual dysfunction |
| JP2007533686A (ja) | 2004-04-22 | 2007-11-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 性的障害ｉｉ治療用の新規医薬組成物 |
| BRPI0511079A (pt) | 2004-05-11 | 2007-12-26 | Emotional Brain Bv | usos de uma combinação de um inibidor de pde5 e testosterona ou de um seu análogo, e de testosterona ou de um seu análogo, formulação farmacêutica, e, kit de partes |
| JP2008536851A (ja) * | 2005-04-13 | 2008-09-11 | ユニメド ファーマスーティカルズ インク | 女性でテストステロンおよび関連ステロイドの濃度を増加させる方法 |
| WO2006127057A1 (en) | 2005-05-24 | 2006-11-30 | Lyle Corporate Drvelopment, Inc. | Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction |
| WO2006125642A1 (en) * | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
| WO2007054791A2 (en) | 2005-11-08 | 2007-05-18 | L'oréal | Androgen glucuronides as markers of androgenic activity |
| EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
| WO2009068520A2 (en) | 2007-11-28 | 2009-06-04 | Schwarz Pharma Ag | Polymorphic form of rotigotine |
-
2005
- 2005-05-11 BR BRPI0511079-3A patent/BRPI0511079A/pt not_active Application Discontinuation
- 2005-05-11 RU RU2006143652/15A patent/RU2436579C2/ru active
- 2005-05-11 SI SI200531779T patent/SI1750766T1/sl unknown
- 2005-05-11 MX MX2013000851A patent/MX347237B/es unknown
- 2005-05-11 PT PT57454670T patent/PT1750766E/pt unknown
- 2005-05-11 RS RS20130420A patent/RS52945B/en unknown
- 2005-05-11 KR KR1020067025958A patent/KR101292492B1/ko active IP Right Grant
- 2005-05-11 MX MXPA06013133A patent/MXPA06013133A/es active IP Right Grant
- 2005-05-11 NZ NZ551356A patent/NZ551356A/en not_active IP Right Cessation
- 2005-05-11 CN CN200580018927.7A patent/CN101027061B/zh active Active
- 2005-05-11 WO PCT/NL2005/000355 patent/WO2005107810A2/en active Application Filing
- 2005-05-11 DK DK05745467.0T patent/DK1750766T3/da active
- 2005-05-11 PL PL05745467T patent/PL1750766T3/pl unknown
- 2005-05-11 EP EP05745467.0A patent/EP1750766B1/en active Active
- 2005-05-11 CA CA2566699A patent/CA2566699C/en active Active
- 2005-05-11 AU AU2005239962A patent/AU2005239962B2/en active Active
- 2005-05-11 CN CN2012100087326A patent/CN102512681A/zh active Pending
- 2005-05-11 ES ES05745467T patent/ES2429444T3/es active Active
- 2005-05-11 JP JP2007513085A patent/JP2007537247A/ja not_active Withdrawn
-
2006
- 2006-11-10 US US11/595,778 patent/US8227453B2/en active Active
- 2006-11-29 ZA ZA200609972A patent/ZA200609974B/xx unknown
-
2008
- 2008-02-27 HK HK08102164.8A patent/HK1108128A1/xx not_active IP Right Cessation
-
2011
- 2011-08-08 RU RU2011133242A patent/RU2636501C2/ru active
-
2012
- 2012-06-21 US US13/529,813 patent/US9192669B2/en active Active
-
2013
- 2013-05-23 JP JP2013108887A patent/JP5923459B2/ja active Active
- 2013-09-20 HR HRP20130892TT patent/HRP20130892T1/hr unknown
- 2013-10-02 CY CY20131100849T patent/CY1114448T1/el unknown
-
2015
- 2015-01-20 JP JP2015008375A patent/JP6166739B2/ja active Active
- 2015-09-25 US US14/866,547 patent/US9700566B2/en active Active
-
2017
- 2017-06-12 US US15/620,576 patent/US10441592B2/en active Active
-
2019
- 2019-09-06 US US16/563,638 patent/US20190388435A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130892T1 (hr) | Farmaceutske formulacije i njihove upotrebe u lijeäśenju ženske seksualne disfunkcije | |
| WO2008022256A3 (en) | Methods and compositions for preventing or treating age-related diseases | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| UA94916C2 (ru) | Композиция тразодона для введения один раз в день | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| CA2668320A1 (en) | Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction | |
| WO2007103200A3 (en) | Oral controlled release formulation for sedative and hypnotic agents | |
| TN2009000137A1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| TW200602022A (en) | Use of PDE III inhibitor for the reduction of heart size in mammals suffering from heart failure | |
| WO2008157537A3 (en) | Compositions and methods of use for treating or preventing lipid related disorders | |
| WO2008124505A3 (en) | Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders | |
| WO2012005500A3 (ko) | 다폭세틴을 포함하는 시간차 서방출 경구투여형 약학적 조성물 | |
| UA90858C2 (ru) | Композиция с контролируемым высвобождением варденафила | |
| HRP20050781B1 (hr) | Metode i farmaceutske mješavine za pouzdano postizanje prihvatljivih razina testosterona u serumu | |
| SI2529622T1 (en) | Bruton tyrosine kinase inhibitors | |
| MX2007012300A (es) | Uso de nefopam y analogos del mismo para el tratamiento de un sindrome caracterizado por dolor cronico y fatiga. | |
| HK1057899A1 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
| SG158863A1 (en) | Intravenous formulations of pde-5 inhibitors | |
| HK1087702A1 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
| BR0315580A (pt) | Derivados de metileno uréia | |
| WO2006070325A3 (en) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
| TW200626158A (en) | Naphthaline derivatives | |
| EA200870368A1 (ru) | Антибиотические композиции с модифицированным высвобождением и способ их получения | |
| WO2008116890A3 (en) | Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders | |
| TW200637817A (en) | 5-aminoindole derivatives |